Evotec SE (EVO) Liabilities from Discontinued Operations (2024 - 2025)
Evotec SE's (EVO) quarterly Liabilities from Discontinued Operations came in at $46.9 million in Q3 2025, up 474.87% year-over-year from $8.2 million in Q3 2024, and up 474.87% quarter-over-quarter from $8.2 million in Q3 2024.
Powered by 
Analysis
Evotec SE (EVO) Liabilities from Discontinued Operations (2024 - 2025) Analysis & Trends
Evotec SE has disclosed Liabilities from Discontinued Operations across 2 years of filings, most recently posting $46.9 million for Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |